| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
BPDBA targets the betaine/GABA transporter 1 (BGT-1), also known as GAT2 in mice. BGT-1 is a sodium- and chloride-dependent transporter that mediates the uptake of GABA and betaine across cell membranes. By inhibiting BGT-1, BPDBA increases the extracellular concentration of GABA, enhancing GABAergic neurotransmission. This mechanism is believed to contribute to anticonvulsant effects, as BGT-1 has emerged as an interesting target for treating epilepsy based on animal studies.
|
|---|---|
| ln Vitro |
In vitro, BPDBA is a selective and noncompetitive inhibitor of BGT-1 with IC50 values of 20 µM for human BGT-1 and 35 µM for mouse GAT2. Its activity is characterized by its ability to inhibit GABA and betaine uptake in cells expressing BGT-1. The compound's noncompetitive mechanism of action means it binds to a site distinct from the substrate binding site, potentially offering advantages for therapeutic development. Its selectivity for BGT-1 over other GABA transporters is a key feature of its pharmacological profile.
|
| ln Vivo |
It is anticipated that BPDBA will exhibit strong blood-brain barrier characteristics and barrier absorption [1].
In vivo, BPDBA has been studied for its potential anticonvulsant effects. BGT-1 inhibitors have been shown to have anticonvulsant effects in animal models of epilepsy. By increasing extracellular GABA levels, BPDBA may enhance inhibitory neurotransmission and reduce seizure activity. The compound's ability to cross the blood-brain barrier is an important factor for its in vivo efficacy. Specific in vivo efficacy data for BPDBA is not detailed in the provided search results. |
| Enzyme Assay |
The in vitro activity of BPDBA is assessed using cell-based GABA and betaine uptake assays. Cells expressing BGT-1 (e.g., HEK293 cells transfected with human BGT-1) are cultured in appropriate media. Cells are incubated with radiolabeled GABA (e.g., [³H]GABA) or betaine in the presence of varying concentrations of BPDBA. The uptake of the radiolabeled substrate is measured, and the IC50 is determined from dose-response curves. For selectivity profiling, the compound is tested against other GABA transporters (GAT1, GAT2, GAT3) to assess its selectivity for BGT-1.
|
| Cell Assay |
For cellular assays, HEK293 cells or other cell lines expressing BGT-1 are cultured in appropriate media. Cells are seeded in 96-well plates and treated with various concentrations of BPDBA (typically 0.1-1000 µM) for 15-30 minutes before the addition of radiolabeled GABA or betaine. After incubation, cells are washed, and the accumulated radioactivity is measured by scintillation counting. The IC50 is determined from dose-response curves. Cell viability is assessed using standard assays.
|
| Animal Protocol |
In vivo, BPDBA is typically administered intraperitoneally or orally to animal models of epilepsy. In seizure models (e.g., maximal electroshock, pentylenetetrazol-induced seizures, or kindling models), the compound is administered at various doses, and seizure activity is monitored. The anticonvulsant effect is assessed by measuring seizure threshold, latency to seizure onset, seizure severity, or survival. Pharmacokinetic studies involve measurement of BPDBA levels in plasma and brain by LC-MS/MS.
|
| ADME/Pharmacokinetics |
BPDBA has a molecular weight of 363.28 g/mol and a molecular formula of C19H20Cl2N2O. It is soluble in DMSO at 27.5 mg/mL (75.7 mM). The compound should be stored as a powder at -20°C under desiccated conditions. Specific pharmacokinetic parameters such as bioavailability, half-life, and volume of distribution are not detailed in the provided search results. The compound's ability to cross the blood-brain barrier is expected based on its lipophilicity.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for BPDBA is not available in the provided search results. As a GABA transporter inhibitor, it may affect GABAergic neurotransmission in the brain, potentially leading to side effects such as sedation, ataxia, or cognitive impairment. The compound is intended for research purposes only and is not approved for human or veterinary use. Standard laboratory safety precautions should be followed when handling the compound. Comprehensive toxicological studies are required to establish its full safety profile.
|
| References | |
| Additional Infomation |
Inhibits betaine-GABA transporter 1; structure as described in the first source.
BPDBA is a research compound that has been developed as a selective BGT-1 inhibitor for the potential treatment of epilepsy. BGT-1 is a promising target for anticonvulsant therapy, as its inhibition increases extracellular GABA levels and enhances inhibitory neurotransmission. BPDBA is not approved for clinical use and is intended for research purposes only. It is available from chemical suppliers for research applications. |
| Molecular Formula |
C19H20N2OCL2
|
|---|---|
| Molecular Weight |
363.281
|
| Exact Mass |
362.1
|
| Elemental Analysis |
C, 62.82; H, 5.55; Cl, 19.52; N, 7.71; O, 4.40
|
| CAS # |
312281-74-6
|
| Related CAS # |
312281-74-6;
|
| PubChem CID |
1069892
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
406
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CN(CCC1NC(=O)C2=C(C=C(C=C2)Cl)Cl)CC3=CC=CC=C3
|
| InChi Key |
OIDACLQVAGIDMT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H20Cl2N2O/c20-15-6-7-17(18(21)12-15)19(24)22-16-8-10-23(11-9-16)13-14-4-2-1-3-5-14/h1-7,12,16H,8-11,13H2,(H,22,24)
|
| Chemical Name |
N-(1-benzylpiperidin-4-yl)-2,4-dichlorobenzamide
|
| Synonyms |
BPDBA;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~275.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7527 mL | 13.7635 mL | 27.5270 mL | |
| 5 mM | 0.5505 mL | 2.7527 mL | 5.5054 mL | |
| 10 mM | 0.2753 mL | 1.3763 mL | 2.7527 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
